FibroBiologics Inc. has received a notification from The Nasdaq Stock Market LLC indicating that the company has failed to meet the minimum closing bid price requirement of $1.00 per share for the past 30 consecutive trading days. Despite this, FibroBiologics' shares will continue to be listed on the Nasdaq Capital Market as long as the company complies with other listing requirements. The company now has until December 29, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If compliance is not achieved by this deadline, FibroBiologics may qualify for an additional 180-day compliance period, provided it meets other listing criteria. Failure to meet these conditions could result in the delisting of the company's securities, although FibroBiologics has the option to appeal such a decision.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.